Publications

• California Judge Allows Public Nuisance Claims Against Social Media Companies
  22 November 2024
  Lindsay Cooper Hayman
  ,
  Maura Kathleen Monaghan
  ,
  John (Jay) Neukom
  ,
  Abraham Tabaie
  ,
  Barbara N. Barath
  ,
  Carter Burwell
  ,
  Jacob W. Stahl
  ,
  Kaitlyn McGill
  ,
  Allison Miller
• Westlaw: The Death of Chevron: Implications of the Loper Decision for Public Companies
  17 September 2024
  Westlaw
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• MarketCheck – Summer 2024
  August 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Jyotin Hamid
  ,
  Emily F. Huang
  ,
  Stephen M. Jordan
  ,
  Maurizio Levi-Minzi
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Jeffrey J. Rosen
  ,
  Zachary H. Saltzman
  ,
  Shannon Rose Selden
  ,
  Matthew J. Sorensen
  ,
  Katherine Durnan Taylor
  ,
  Alison E. Buckley-Serfass
  ,
  Caroline P. Geiger
  ,
  Caitlin Gibson
  ,
  Anne-Mette Heemsoth
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jillian Mulroy Wright
  ,
  Ilya Balabanovsky
  ,
  Marisa Demko
  ,
  Katrina Mari Kaczynski
  ,
  Rekha Korlipara
• 2024 Private Equity Midyear Outlook
  August 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Christopher Dortschy
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Andrew J. Gershon
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Arian M. June
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Gregory J. Lyons
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Sheena Paul
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Paul D. Rubin
  ,
  Scott B. Selinger
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Rick Sofield
  ,
  Katherine Durnan Taylor
  ,
  Ramya S. Tiller
  ,
  Jonathan R. Tuttle
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Jennifer Wheater
  ,
  Naomi Aoyama
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Zhiyan Cao
  ,
  Jennifer R. Cestaro
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  Stuart Hammer
  ,
  Lauren P. Heller
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Michael P. McGuigan
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  John Young
  ,
  Ulysses Smith
  ,
  Kayleigh Anderson
  ,
  Hymie A. Anteby
  ,
  Jabari Benjamin
  ,
  Charles Cartiglia
  ,
  Josephine Chen
  ,
  Jordan Corrente Beck
  ,
  Tejas N. Dave
  ,
  Julia Glazer
  ,
  Michael C. Godbe
  ,
  Zoe Jacoby
  ,
  Yiran Ji
  ,
  Adriana Kranjac
  ,
  Paul D. Lowry
  ,
  Kaitlyn McGill
  ,
  Diana Moise
  ,
  Amy Pereira
  ,
  John M. Satira
  ,
  Eike Björn Weidner
  ,
  Keith Moshe
• Law360: After Chevron: FDA Regulations In The Crosshairs
  8 July 2024
  Law360
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• Insurance Industry Corporate Governance Newsletter
  2 July 2024
  Morgan A. Davis
  ,
  Eric Dinallo
  ,
  Maura Kathleen Monaghan
  ,
  Nicholas F. Potter
  ,
  Erica S. Weisgerber
• Supreme Court Holds That Insurers Have Standing to Object to Chapter 11 Bankruptcy Plans
  11 June 2024
  Maura Kathleen Monaghan
  ,
  Erica S. Weisgerber
  ,
  Morgan A. Davis
• Increased FCA Enforcement Targeting PE Firms Expected in 2024
  11 March 2024
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Shannon Rose Selden
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Kaitlyn McGill
• Private Equity Report: 2024 Outlook
  February 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Paul S. Bird
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Charu A. Chandrasekhar
  ,
  Jennifer L. Chu
  ,
  Luke Dembosky
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Avi Gesser
  ,
  Andrew J. Gershon
  ,
  Nia I. Goodman
  ,
  David Grosgold
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Jonathan F. Lewis
  ,
  Sidney P. Levinson
  ,
  Andrew M. Levine
  ,
  Erez Liebermann
  ,
  Timothy McIver
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Natalie L. Reid
  ,
  Julie M. Riewe
  ,
  Kevin Rinker
  ,
  Samantha J. Rowe
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Aly Love (f/k/a Simons)
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Kyra K. Bromley
  ,
  Alison E. Buckley-Serfass
  ,
  Jennifer R. Cestaro
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Michael P. McGuigan
  ,
  Sheena Paul
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Sergio Torres
  ,
  Elie J. Worenklein
  ,
  Adam Aukland-Peck
  ,
  Josephine Chen
  ,
  Perpétua B. Chéry
  ,
  Paul Eastham
  ,
  Isabelle Glimcher
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Leah Martin
  ,
  Sophie Michalski
  ,
  Diana Moise
  ,
  David J. Swiedler
  ,
  Perri M. Weinstein
  ,
  Nathan R. Hogan
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac
  ,
  Kaitlyn McGill
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Ilya Balabanovsky
  ,
  Margaret Howard
  ,
  Chaim Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• Law360: What Banks Should Know About TCPA Exam Policy Updates
  13 December 2023
  Law360
  Maura Kathleen Monaghan
  ,
  Caroline N. Swett
  ,
  Jacob W. Stahl
• New York Law Journal: Artificial Intelligence in Class Action Litigation
  8 December 2023
  New York Law Journal
  Jim Pastore
  ,
  Maura Kathleen Monaghan
• OCC Issues Revised TCPA Examination Procedures: What Bank Compliance Personnel Should Know
  15 November 2023
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Caroline N. Swett
  ,
  Jacob W. Stahl
  ,
  Emma Macfarlane
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• 2023 Private Equity Midyear Outlook
  27 July 2023
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Jeffrey P. Cunard
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Andrew J. Gershon
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Emily F. Huang
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  Rafael Kariyev
  ,
  Meir D. Katz
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Julie M. Riewe
  ,
  Shannon Rose Selden
  ,
  Steven J. Slutzky
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  J. Michael Snypes, Jr.
  ,
  Patrick Taylor
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Erica S. Weisgerber
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Zhiyan Cao
  ,
  Robert T. Dura
  ,
  Stuart Hammer
  ,
  Megan McGuiggan
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Jacob W. Stahl
  ,
  Sergio Torres
  ,
  Jennifer Wheater
  ,
  Elie J. Worenklein
  ,
  Adam Aukland-Peck
  ,
  Colleen B. Bernaiche
  ,
  Charles Cartiglia
  ,
  Paul Eastham
  ,
  Jay E. Evans
  ,
  Sara Ewad
  ,
  Christopher Gossage
  ,
  Camila Isern
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Rekha Korlipara
  ,
  Adriana Kranjac
  ,
  Samuel D. Krawiecz
  ,
  Harshil Mehta
  ,
  Gianni Pizzitola
  ,
  Stanley G. Seckler
  ,
  Sheng Shao
  ,
  Massy Vainshtein
• Legal Dispute Surrounding Abortion Pill Has Significant Implications for Broader Healthcare Industry
  9 May 2023
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Melissa Runsten
• Reuters: The new frontier of fraud, waste and abuse: COVID-related misconduct enforcement trends
  27 March 2023
  Reuters
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Adam Aukland-Peck
  ,
  Hannah R. Levine
• New York Seeks Review and Approval Authority over Certain Healthcare Transactions
  7 March 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Proceed with Caution: Online Tracking Technologies Pose HIPAA Compliance Risks
  2 March 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
• Practising Law Institute: Privacy Law Answer Book
  23 January 2023
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Jyotin Hamid
  ,
  Satish M. Kini
  ,
  Henry Lebowitz
  ,
  Erez Liebermann
  ,
  Maura Kathleen Monaghan
  ,
  David A. O'Neil
  ,
  Jim Pastore
  ,
  David Sarratt
  ,
  Jeffrey P. Cunard
  ,
  Kim T. Le
  ,
  Tricia Bozyk Sherno
  ,
  Johanna N. Skrzypczyk
  ,
  Michael Bloom
  ,
  Fanny Gauthier
  ,
  Hannah R. Levine
  ,
  Linda Lin
  ,
  Kate Saba
  ,
  Noah L. Schwartz
  ,
  Mengyi Xu
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Samuel J. Allaman
  ,
  Adam Aukland-Peck
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Adrian St. Francis
  ,
  Emily G. Dennan
  ,
  Micah A. Rubin
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Private Equity Report Fall 2022, Vol 22, No 3
  November 2022
  Andrew L. Bab
  ,
  Sally Bergmann Hardesty
  ,
  Michael Bolotin
  ,
  Jennifer L. Chu
  ,
  Erin Cleary
  ,
  Matthew Dickman
  ,
  Gregory V. Gooding
  ,
  Mark P. Goodman
  ,
  Gareth Hughes
  ,
  Mark Johnson
  ,
  Meir D. Katz
  ,
  Henry Lebowitz
  ,
  Maurizio Levi-Minzi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Ramya S. Tiller
  ,
  Zhiyan Cao
  ,
  Caroline P. Geiger
  ,
  Kim T. Le
  ,
  Jin-Hyuk Jang
  ,
  Tigist Kassahun
  ,
  Hannah R. Levine
  ,
  Keith J. Slattery
  ,
  Sergio Torres
  ,
  Dominique Trudelle
  ,
  Hadel Alfagir
  ,
  David N. Simpser
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• FTC Sharpens Focus on Private Equity
  17 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Leah Martin
  ,
  Adam C. Saunders
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Adriana Kranjac
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• The Supreme Court TransUnion Case: Part 2—What It Means for Efforts to Defeat Class Certification?
  9 July 2021
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Benjamin Leb
• Law360: TCPA Litigation And Compliance After Facebook Ruling
  13 April 2021
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• The Supreme Court Rules for Facebook: What It Means for TCPA Compliance and Class Certification Defense
  7 April 2021
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Benjamin Leb
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Eleventh Circuit Precludes “Administrative Feasibility” but Provides a Path Forward for Defendants Opposing Class Certification in Consumer Class Actions
  9 February 2021
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jennifer L. Chu
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Federal Government Shines Spotlight on Speaker Programs
  20 November 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Supreme Court Acts Twice on the TCPA: What It Means for Automated Callers, the First Amendment, and Statutory Challengers
  10 July 2020
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
• Reopening Schools in the COVID-19 Climate: Legal Issues to Consider
  16 June 2020
  Mary Beth Hogan
  ,
  Maura Kathleen Monaghan
  ,
  Elliot Greenfield
  ,
  Tricia Bozyk Sherno
  ,
  Amy C. Zimmerman
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: CMS Expands Medicare Coverage for Telehealth Services amid Public Health Emergency
  20 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: FDA Developments and Legal Considerations for Healthcare and Life Science Companies and Investors
  17 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Suchita Mandavilli Brundage
  ,
  Melissa Runsten
• Ninth Circuit Decision Increases Risk of RICO Economic Loss Claims Against Pharmaceutical Manufacturers and Highlights Evolving Circuit Split
  6 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• Law360: Health Care AI Increasingly In Crosshairs Of State, Fed. Gov't
  9 January 2020
  Law360
  Maura Kathleen Monaghan
  ,
  Jim Pastore
• What the Bipartisan Budget Agreement Means for the Healthcare Industry and Life Sciences Companies
  23 December 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Leah Martin
• Have Your Say on CCPA
  18 November 2019
  Jeffrey P. Cunard
  ,
  Luke Dembosky
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Kate Saba
• Delaware Court of Chancery Sustains Failure to Monitor Caremark Claim
  22 October 2019
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jonathan R. Tuttle
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Congressional Investigation Highlights Potential Risks for Private Equity Healthcare Investments
  19 September 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Maura Kathleen Monaghan
  ,
  David A. O'Neil
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Jacob W. Stahl
• Not With a Bang But a Whimper: At the Deadline, Minor Amendments to the California Consumer Privacy Act
  18 September 2019
  Jeffrey P. Cunard
  ,
  Luke Dembosky
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jane Shvets
• Court Strikes Down Regulation Requiring Price Disclosure in TV Ads for Prescription Drugs
  11 July 2019
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jyotin Hamid
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The California Consumer Privacy Act: Compliance Strategies for Financial Institutions
  2 May 2019
  Luke Dembosky
  ,
  Satish M. Kini
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jane Shvets
• Affordable Care Act Likely to Survive Latest Challenge
  19 December 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Life Sciences Companies Can Prepare For Legal And PR Crises
  13 December 2018
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Life Sciences Cos. Can Prepare For Legal And PR Crises
  December 13, 2018
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Medical Device Cybersecurity Report Advancing Coordinated Vulnerability Disclosure
  4 December 2018
  Luke Dembosky
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Managing the Minefield: How Life Sciences Companies Can Be Prepared for Legal and Public Relations Crises
  30 November 2018
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies
  19 November 2018
  Bloomberg Law
  Andrew J. Ceresney
  ,
  Maura Kathleen Monaghan
  ,
  Paul M. Rodel
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• A Post-Election Survey Of The Health Care Ecosystem
  9 November 2018
  Law360
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The 2018 Elections: Winners and Losers in the Healthcare Ecosystem
  9 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Part B Price Controls: Hurdles and Unintended Consequences
  5 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Rule Regarding Disclosure of Drug “List Prices” in Television Ads: Needed Transparency or Recipe for Confusion?
  23 October 2018
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• Amendments to the California Consumer Privacy Act of 2018
  26 September 2018
  Luke Dembosky
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jane Shvets
• Privacy Law Goes Big: California’s New Consumer Privacy Act
  3 July 2018
  Luke Dembosky
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jane Shvets
• Fourth Circuit Decision Casts Doubt on State Efforts to Regulate Drug Pricing
  18 May 2018
  Bloomberg Law
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The White House’s Drug Pricing “Blueprint”
  18 May 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Debevoise Hosts Panel on Confronting Bias in AI
  Maura Kathleen Monaghan
• D.C. Circuit Court Decision May Help Level the Playing Field for TCPA Defendants
  29 March 2018
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• DOJ Memorandum Addressing Agency Guidance
  9 March 2018
  Compliance & Enforcement
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• DOJ Memorandum Addressing Agency Guidance
  8 March 2018
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• False claims, investigations and enforcements
  February 2018
  Financier Worldwide
  Maura Kathleen Monaghan
• Perpetually Liable? What the California Supreme Court Decision Means for Innovator Pharmaceutical Companies
  22 February 2018
  Toxics Law Reporter
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Latest on the Trump Administration’s Drug Pricing Initiatives
  21 February 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• DOJ Creates Potential Opening For Early Dismissal of False Claims Act Suits
  1 February 2018
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• T.H. v. Novartis: Implications for Companies That Have Sold or Are Considering Selling the Rights to Innovator Drugs
  19 January 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• A Look At Recent Efforts To Contain Health Care Costs
  5 January 2018
  Law360
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Tax Reform and Other Recent Developments Could Impact the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• New Public and Private Efforts to Contain Healthcare Costs: What it Means for the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The “Tax Cuts and Jobs Act” – How It Impacts the Healthcare Industry
  7 November 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Gary M. Friedman
  ,
  Peter A. Furci
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Where Does Healthcare Reform Stand?
  31 October 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• How Section 1332 Waivers Could Impact Health Care Reform
  24 July 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Health Care Winners And Losers From The Better Care Act
  29 June 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The “Better Care Act”: Winners and Losers in the Healthcare Industry
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Senate’s Healthcare Bill – What’s In It?
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Supreme Court Limits Forum Shopping, Creates Risk Management Opportunities
  23 June 2017
  Maura Kathleen Monaghan
  ,
  William H. Taft V
  ,
  Jacob W. Stahl
• The United States Withdraws From the Paris Agreement on Climate Change
  2 June 2017
  Catherine Amirfar
  ,
  Maura Kathleen Monaghan
  ,
  David W. Rivkin
• Finally A Health Care Reform Plan Passes the House – What’s in the Bill and What it Means for the Healthcare Industry
  5 May 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Shining A Light On GOP Plan For Health Care Reform
  7 March 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Just a Bit of Clarity – Recent Developments Shine Some Light on Trump and GOP Plans for Healthcare Reform
  27 February 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• The Outlook For The Pharmaceutical Industry Under Trump
  12 January 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Outlook On Drug Pricing: At What Cost?
  14 December 2016
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Still in the Waiting Room: Outlook for the Healthcare Industry Under the Trump Administration
  15 November 2016
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Gary M. Friedman
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration Is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent
  7 October 2016
  Bloomberg BNA Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Helen V. Cantwell
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• New Federal Ransomware Guidance
  19 July 2016
  Luke Dembosky
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
• FDA’s New Guidance On Cybersecurity For Medical Devices: Important Lessons For The Entire Healthcare Industry
  25 April 2016
  Bloomberg BNA Health IT Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Florida Court Dismisses Data Breach Lawsuit for Lack of Standing
  29 February 2016
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Elliot Greenfield
  ,
  David Sarratt
• Canada Vs. US Product Liability: Recent Developments
  25 January 2016
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Christel Y. Tham
• FDA Publishes Guidance on Postmarket Cybersecurity Risk Management for Medical Device Manufacturers
  25 January 2016
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Supreme Court Rules that Unaccepted Rule 68 Offers of Complete Relief Do Not Moot a Plaintiff’s Case – But Payment of Full Relief Just May
  25 January 2016
  David H. Bernstein
  ,
  Jeffrey P. Cunard
  ,
  Courtney M. Dankworth
  ,
  Jyotin Hamid
  ,
  Mary Beth Hogan
  ,
  Maura Kathleen Monaghan
  ,
  Erol Gulay
• Canada Vs. US Product Liability: The Canadian Experience
  22 January 2016
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Christel Y. Tham
• Canada Vs. US Product Liability: The US Experience
  21 January 2016
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Christel Y. Tham
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  12 January 2016
  American Bar Association
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Speedy Returns: The 60-Day Rule
  January 12 2016
  American Bar Association
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Avoiding And Defeating Securities Fraud Actions Against Clinical-Stage Biopharmaceutical Companies
  10 July 2015
  Bloomberg BNA Life Sciences Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  William H. Taft V
  ,
  Jacob W. Stahl
• First Circuit Holds That Federal Law Preempts State-Law Claims Involving a Branded Drug Label
  4 March 2015
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• Ninth Circuit Affirms District Court Order to Unwind Hospital Merger
  13 February 2015
  Gary W. Kubek
  ,
  Mark P. Goodman
  ,
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kristin D. Kiehn
  ,
  Erica S. Weisgerber
• Breaking Ranks: Garlock Reaches Unprecedented Deal with Future Claims Representative on Value of Trust for Asbestos Claims
  21 January 2015
  Mark P. Goodman
  ,
  M. Natasha Labovitz
  ,
  Maura Kathleen Monaghan
  ,
  Shannon Rose Selden
• Food For Thought: Corporate Executives On Notice That DOJ Will Seek To Hold Them Criminally Liable for Contaminated Food Outbreaks And Product Failures
  14 November 2014
  Bloomberg BNA’s White Collar Crime Report
  Helen V. Cantwell
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  14 November 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments
  17 September 2014
  Bloomberg BNA’s Health Care Fraud Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• FDA Issues Proposed Guidance on Social Media and Internet Communications for Pharmaceutical and Medical Device Manufacturers
  27 June 2014
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• To File or Not to File: the Forum Non Conveniens Dilemma
  May 2014
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor
  4 April 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Newly Affirmed Bankruptcy Court Ruling Outlines Path to Bankruptcy Discharge for Mass Tort Claims
  18 February 2014
  Jasmine Ball
  ,
  Richard F. Hahn
  ,
  M. Natasha Labovitz
  ,
  George E.B. Maguire
  ,
  Maura Kathleen Monaghan
  ,
  Shannon Rose Selden
  ,
  Craig A. Bruens
• Court Rules that Due to Misrepresentations by Plaintiffs’ Firms, Garlock’s Settlement History Does Not Accurately Represent Its Actual Asbestos Liability
  February/March 2014
  Pratt’s Journal of Bankruptcy Law.
  Mark P. Goodman
  ,
  M. Natasha Labovitz
  ,
  Maura Kathleen Monaghan
• Court Rules That Due to Misrepresentations by Plaintiffs’ Firms, Garlock’s Settlement History Does Not Accurately Represent Its Actual Asbestos Liability
  21 January 2014
  Maura Kathleen Monaghan
  ,
  Mark P. Goodman
  ,
  M. Natasha Labovitz
• Handling State AG Parens Patriae Actions Now That the Supreme Court Has Rejected Federal Court Removal
  21 January 2014
  Mark P. Goodman
  ,
  John S. Kiernan
  ,
  Maura Kathleen Monaghan
  ,
  Erica S. Weisgerber
• Enforcement without Guidance: The FDA’s Policing of Online Pharmaceutical Advertisements and Communications
  20 December 2013
  Bloomberg BNA Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Did the Third Circuit Just Impose a Proof-of-Purchase Requirement in Consumer Product Class Actions?
  6 August 2013
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
• Supreme Court Expands “Impossibility” Preemption to Design Defect Claims against Generic Drug Manufacturers
  26 June 2013
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• Ninth Circuit Rejects Lodestar Fees in Coupon Class Action Settlements
  16 May 2013
  Maura Kathleen Monaghan
• Third Circuit Rejects Baby Products Antitrust Class Action Settlement
  20 February 2013
  Gary W. Kubek
  ,
  Maura Kathleen Monaghan
• Second Circuit Concludes Truthful Off-Label Promotion Is Not Unlawful: Free Speech, But Not A Free Pass (Yet)
  5 December 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Andrew M. Levine
  ,
  Kristin D. Kiehn
• Second Circuit: Class Action Notice Must Be Published More Widely Than Just in USA Today
  20 August 2012
  Maura Kathleen Monaghan
  ,
  Erica S. Weisgerber
• GSK's $3 Billion Settlement Reflects Continued Expansion In Scope Of Pharma Plea Agreements
  August 2012
  Rx Compliance Report
  Kristin D. Kiehn
  ,
  Maura Kathleen Monaghan
  ,
  Mark P. Goodman
• GSK $3 Billion Settlement Reflects Continued Expansion in Scope of Pharma Plea Agreements
  9 July 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• No Shortcuts to Class Notice: Third Circuit Orders Sprint to Spend More Time and Money Identifying More Potential Class Members
  2 July 2012
  John S. Kiernan
  ,
  Maura Kathleen Monaghan
• Supreme Court Upholds 2010 Patient Protection and Affordable Care Act
  29 June 2012
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
• An Unprecedented Settlement For FDCA Violation
  22 May 2012
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Abbott Settlement Includes Unprecedented Term of Probation, Mandatory Compliance Measures
  10 May 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Honda Drives Ninth Circuit to Reject Certification of Nationwide Consumer Class
  13 January 2012
  Maura Kathleen Monaghan
• Supreme Court Rules in Two Pharma Cases
  29 June 2011
  Anne E. Cohen
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Deliberate, Decide… and Disclose? The Limitations of the Deliberative Process Privilege
  Spring 2011
  ABA Mass Torts Newsletter
  Maura Kathleen Monaghan
• Limitations of the Deliberative Process Privilege
  Spring 2011
  ABA's Mass Torts Litigation newsletter
  Maura Kathleen Monaghan
• Bruesewitz v. Wyeth: Express Preemption Returns to the Fore
  23 February 2011
  Maura Kathleen Monaghan
  ,
  Roger E. Podesta
  ,
  Mark P. Goodman
  ,
  Anne E. Cohen
  ,
  Mary Beth Hogan
  ,
  Kristin D. Kiehn
• Are Nationwide State-Law Classes Tenable Even for Settlement Purposes? The Third Circuit Rejects One but Leaves a Partially Open Door
  15 July 2010
  Gary W. Kubek
  ,
  Maura Kathleen Monaghan
• True to Word: AGs Curtailing Coupon Settlements
  8 January 2010
  Product Liability Law360
  John S. Kiernan
  ,
  Maura Kathleen Monaghan
• True to Their Word: State Attorneys General Move to Block Another Class Action “Coupon Settlement”
  4 January 2010
  John S. Kiernan
  ,
  Maura Kathleen Monaghan
• Wyeth v Levine: The Road Ahead
  3 April 2009
  Scrip World Pharmaceutical News
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
• Wyeth v Levine: The Road Ahead
  26 March 2009
  ScripNews.com
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
• Wyeth v. Levine: Not the End of Preemption and Not the End of the World
  10 March 2009
  Maura Kathleen Monaghan
  ,
  Roger E. Podesta
  ,
  Mark P. Goodman
  ,
  Anne E. Cohen
  ,
  Mary Beth Hogan